16 July 2024
16 July 2024
Article doesn't exist
In line with its mission to provide vaccines affordably, SII is offering R21/Matrix-M at less than $4 per dose.
The move strengthens AstraZeneca’s late-stage pipeline within its Alexion rare disease division.
The company will initiate Phase Ib and Phase II studies in major depression in 2024 and 2025, respectively.
The company is seeking regulatory approval in the US and EU for Rinvoq as a treatment for giant cell arteritis.
The partnership will combine Nona's HCAb Harbour Mice platform with Alaya.bio's polymeric delivery platform.
The company plans to use the proceeds to advance the clinical development of OGA inhibitors.
DSP-5336 inhibitor targets the menin and MLL protein interaction that is crucial in gene expression.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
